CRISPR Therapeutics AG (CRSP) Share-based Compensation (2015 - 2026)

CRISPR Therapeutics AG has disclosed Share-based Compensation across 12 years of filings, most recently posting $17.3 million for Q2 2026.

• In Q2 2026, Share-based Compensation fell 1.65% year-over-year to $17.3 million; the TTM figure through Jun 2026 stood at $68.3 million (down 16.01% YoY), while the FY2025 annual figure was $72.5 million, down 16.28% from the prior year.
• Share-based Compensation came in at $17.3 million for Q2 2026 at CRISPR Therapeutics AG, up from $16.3 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $25.7 million in Q1 2022 to a low of $16.3 million in Q1 2026.
• Average Share-based Compensation over 5 years is $20.7 million, with a median of $20.5 million recorded in 2023.
• Year-over-year, Share-based Compensation grew 19.33% in 2024 and retreated 25.62% in 2025.
• Over 5 years, Share-based Compensation stood at $22.8 million in 2022, then declined by 19.23% to $18.4 million in 2023, then gained by 19.33% to $22.0 million in 2024, then declined by 17.76% to $18.1 million in 2025, then decreased by 4.21% to $17.3 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $17.3 million in Q2 2026, $16.3 million in Q1 2026, and $18.1 million in Q4 2025.